- Home
- NG vs JANX Comparison
NG vs JANX Comparison
Compare NG & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- JANX
- Stock Information
- Founded
- NG 1984
- JANX 2017
- Country
- NG Canada
- JANX United States
- Employees
- NG N/A
- JANX N/A
- Industry
- NG Precious Metals
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- NG Basic Materials
- JANX Health Care
- Exchange
- NG Nasdaq
- JANX Nasdaq
- Market Cap
- NG 1.5B
- JANX 1.4B
- IPO Year
- NG N/A
- JANX 2021
- Fundamental
- Price
- NG $6.76
- JANX $23.98
- Analyst Decision
- NG Strong Buy
- JANX Strong Buy
- Analyst Count
- NG 2
- JANX 9
- Target Price
- NG $7.00
- JANX $85.00
- AVG Volume (30 Days)
- NG 3.2M
- JANX 705.9K
- Earning Date
- NG 10-01-2025
- JANX 11-05-2025
- Dividend Yield
- NG N/A
- JANX N/A
- EPS Growth
- NG N/A
- JANX N/A
- EPS
- NG N/A
- JANX N/A
- Revenue
- NG N/A
- JANX $439,000.00
- Revenue This Year
- NG N/A
- JANX N/A
- Revenue Next Year
- NG N/A
- JANX $591.60
- P/E Ratio
- NG N/A
- JANX N/A
- Revenue Growth
- NG N/A
- JANX N/A
- 52 Week Low
- NG $2.26
- JANX $21.97
- 52 Week High
- NG $6.95
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- NG 71.73
- JANX 49.92
- Support Level
- NG $6.56
- JANX $22.41
- Resistance Level
- NG $6.95
- JANX $24.00
- Average True Range (ATR)
- NG 0.26
- JANX 1.10
- MACD
- NG 0.02
- JANX 0.01
- Stochastic Oscillator
- NG 82.89
- JANX 42.20
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.